Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

5.010 +0.010 (+0.20%)
Streaming Delayed Price Updated: 10:34 AM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Effect a Reverse Stock Split
From Precision BioSciences, Inc.
Via Business Wire
Earnings Outlook For Precision BioSciences
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Precision BioSciences
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?
TG Therapeutics Inc (NASDAQ: TGTX) reported preliminary BRIUMVI U.S.  
Via Benzinga
Why Precision BioSciences Stock Is Up Today
Precision BioSciences, Inc. (NASDAQ: DTIL) shares are trading higher Tuesday after the company announced it has signed a licensing agreement wit 
Via Benzinga
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at Hep-DART 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at Upcoming Sidoti Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Precision BioSciences to Report Third Quarter Results on November 7, 2023
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases
From Precision BioSciences, Inc.
Via Business Wire
Why Femasys Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket
Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment. 
Via Benzinga
Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Attend and Present at Upcoming September Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023
From Precision BioSciences, Inc.
Via Business Wire
What Is Precision BioSciences CAR T Pipeline Value? Analyst Lowers Price Target To Justify Valuation
Wednesday, Precision BioSciences Inc (NASDAQ: DTIL) announced the completion of a strategic transaction with Imugene Limited for global rights to Azercabtagene Zapreleucel (azer-cel), Precision's lead... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.